A High-Sensitivity Circulating Nucleic Acid Sequencing Assay for Assessing Treatment Response to Alectinib in a Pediatric Patient With ALK-Rearranged Non-Small Cell Lung Cancer.
Sensitive blood testing tracked drug response in a child with lung cancer, suggesting liquid biopsies could work in rare pediatric cases.
Letter describing a single pediatric case where high-sensitivity circulating nucleic acid sequencing tracked alectinib treatment response in ALK-rearranged NSCLC; informative but very limited evidence base. Useful as hypothesis-generating signal for pediatric liquid biopsy applications.
What the study was
- Study design
- Single case report/letter
- Population
- Pediatric patient with ALK-rearranged NSCLC
- Sample size
- 1
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Pediatric Blood & Cancer
Why it surfaced
Letter format, single case report; capped at 4 for case report rule; informative signal only.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.